Loading company…
Nodus Oncology develops molecules targeting DNA damage response pathways for cancer therapies.
Nodus Oncology develops molecules that inhibit novel DNA damage response targets to support cancer therapy development. Its research uses genomic instability and replication stress to investigate vulnerabilities in defined cancer populations. Based in Edinburgh, UK, the company raised GBP 2.4 million in February 2023 from Khanu Management and Cumulus Oncology to advance its PARG program and other targets.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in